Comparative Pharmacology
Head-to-head clinical analysis: DEPEN versus VISTOGARD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPEN versus VISTOGARD.
DEPEN vs VISTOGARD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillamine is a chelating agent that forms soluble complexes with heavy metals (e.g., copper, mercury, lead) and promotes their renal excretion. In rheumatoid arthritis, it reduces rheumatoid factor and immune complexes, and inhibits collagen cross-linking.
Uridine triacetate is a prodrug of uridine, which competes with fluorouracil (5-FU) catabolites for binding to orotate phosphoribosyltransferase, reducing the incorporation of 5-FU metabolites into RNA and DNA, thereby preventing cell death.
250 mg orally 4 times daily, target dose 1000-1500 mg/day in divided doses.
6 g (2 vials) intravenously over 15 minutes as a single dose.
None Documented
None Documented
1.5-4 hours; prolonged to 6-12 hours in renal impairment; clinical context: dosing interval adjustments needed in CKD.
The terminal elimination half-life of uridine triacetate metabolites (primarily uridine and its metabolites) is approximately 2-3 hours. This short half-life supports the need for multiple daily doses (typically 10 doses over 5 days) to maintain therapeutic uridine concentrations.
Renal: 50% as unchanged drug; biliary/fecal: minor, <5%.
Vistogard (uridine triacetate) is primarily excreted via the kidneys as inactive metabolites, with approximately 90% of the administered dose recovered in urine within 24 hours. The remainder is eliminated via feces (about 10%).
Category C
Category C
Chelating Agent
Chelating Agent